The vulnerable plaque and acute coronary syndromes

被引:80
作者
Corti, R
Farkouh, ME
Badimon, JJ
机构
[1] CUNY Mt Sinai Sch Med, Cardiovasc Inst, Cardiovasc Biol Res Lab, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, New York, NY 10029 USA
关键词
D O I
10.1016/S0002-9343(02)01344-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The interaction between the vulnerable atherosclerotic plaque and thrombus formation, a process referred to as atherothrombosis, is the cornerstone of acute coronary syndromes. Advances in noninvasive imaging have helped to identify novel approaches to plaque stabilization, with the potential to prevent plaque rupture, including lifestyle modification and dietary adjustments, as well as pharmacologic interventions such as statins. Following an acute coronary event, strategies combining mechanical and pharmacologic therapies provide considerable advances in prevention of subsequent cardiac events. Pharmacologic strategies to prevent and treat thrombotic complications related to acute coronary syndromes have been developed to dissolve preformed thrombi and to inhibit thrombogenesis. These regimens focus on inhibiting thrombin, preventing thrombi generation, blocking the initiation of coagulation, inhibiting platelet activation, and increasing fibrinolysis. (C)2002 by Excerpta Medica, Inc.
引用
收藏
页码:668 / 680
页数:13
相关论文
共 127 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]   A new paradigm for plaque stabilization [J].
Ambrose, JA ;
Martinez, EE .
CIRCULATION, 2002, 105 (16) :2000-2004
[3]   Thrombosis in ischemic heart disease [J].
Ambrose, JA ;
Weinrauch, M .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (13) :1382-1394
[4]   Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction - TIMI 11B-ESSENCE meta-analysis [J].
Antman, EM ;
Cohen, M ;
Radley, D ;
McCabe, C ;
Rush, J ;
Premmereur, J ;
Braunwald, E .
CIRCULATION, 1999, 100 (15) :1602-1608
[5]   Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery - A randomized controlled trial [J].
Aversano, T ;
Aversano, LT ;
Passamani, E ;
Knatterud, GL ;
Terrin, ML ;
Williams, DO ;
Forman, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (15) :1943-1951
[6]   Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques - Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions [J].
Badimon, JJ ;
Lettino, M ;
Toschi, V ;
Fuster, V ;
Berrozpe, M ;
Chesebro, JH ;
Badimon, L .
CIRCULATION, 1999, 99 (14) :1780-1787
[7]  
BADIMON L, 1998, CARDIOVASCULAR THROM, P23
[8]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[9]   Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. [J].
Bauer, KA ;
Eriksson, BI ;
Lassen, MR ;
Turpie, AGG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (18) :1305-1310
[10]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498